Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any muscular dystrophy-dystroglycanopathy, type A in which the cause of the disease is a mutation in the POMGNT2 gene.
Features include always present findings: Type II lissencephaly, Cerebellar hypoplasia, Progressive muscle deterioration (muscular dystrophy), and Enlarged brain ventricles (ventriculomegaly); and common findings: Low muscle tone (hypotonia), Retinal dysplasia, and Glaucoma. 10 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 3 | Global developmental delay, Hydrocephalus, Enlarged brain ventricles (ventriculomegaly) |
Muscles | 2 | Low muscle tone (hypotonia), Progressive muscle deterioration (muscular dystrophy) |
Eyes | 2 | Retinal dysplasia, Glaucoma |
POMGNT2 function has not been fully characterized.
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 8 is associated with mutations in the POMGNT2 gene on chromosome 3.
Genetic testing for POMGNT2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 8 has been reported in the published literature.
Phenotype severity distribution: 4 always present features, 3 common features.
No clinical trials have been registered for muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 8.
108 publications have been identified in PubMed for muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 8. Kisho has analyzed 41 by research type. Research spans Other (46%), Review / Meta-Analysis (32%), and Clinical Trial Publication (7%).
Research Type | Count | % of Total |
|---|---|---|
Other research | 19 | 46% |
Research summaries | 13 | 32% |
Clinical study results | 3 | 7% |
Patient case studies | 2 | 5% |
Disease patterns and progression | 2 | 5% |
Testing and diagnosis research | 1 | 2% |
Laboratory research | 1 | 2% |
Li S (2026). [PMID: 41379706](https://pubmed.ncbi.nlm.nih.gov/41379706/). *J Fam Psychol*. [Review / Meta-Analysis]
Campbell JI (2025). [PMID: 39509188](https://pubmed.ncbi.nlm.nih.gov/39509188/). *Curr Opin Pediatr*. [Review / Meta-Analysis]
Simes D (2025). [PMID: 39495636](https://pubmed.ncbi.nlm.nih.gov/39495636/). *Psychother Res*. [Other]
Lee SJ (2025). [PMID: 41188778](https://pubmed.ncbi.nlm.nih.gov/41188778/). *BMC Ophthalmol*. [Case Report / Case Series]
Sharaf-Eldin W (2025). [PMID: 39998573](https://pubmed.ncbi.nlm.nih.gov/39998573/). *J Mol Neurosci*. [Review / Meta-Analysis]
Goodrich J (2025). [PMID: 40925213](https://pubmed.ncbi.nlm.nih.gov/40925213/). *Int J Nurs Stud*. [Other]
Liu FQ (2025). [PMID: 40186435](https://pubmed.ncbi.nlm.nih.gov/40186435/). *J Ultrasound Med*. [Clinical Trial Publication]
McMahon EL (2025). [PMID: 41206319](https://pubmed.ncbi.nlm.nih.gov/41206319/). *Curr Probl Pediatr Adolesc Health Care*. [Review / Meta-Analysis]
Zagari F (2025). [PMID: 41178487](https://pubmed.ncbi.nlm.nih.gov/41178487/). *Acta Otorhinolaryngol Ital*. [Other]
Ishigaki K (2025). [PMID: 40011677](https://pubmed.ncbi.nlm.nih.gov/40011677/). *Sci Rep*. [Basic Science / Preclinical]
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 9:35 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center